Daiichi Sankyo Co., Ltd.
https://www.daiichisankyo.com/index.html
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Daiichi Sankyo Co., Ltd.
Rare Diseases Rule, But Some Common Conditions Stand Out In Pending US Applications
Half of the FDA’s upcoming 2024 user fee goals target rare diseases, but highly prevalent conditions like uncomplicated urinary tract infections and atopic dermatitis are also up for agency action in the second half of the year.
Obesity Rules Large-Cap Stocks In First Half Of 2024
Lilly and Novo Nordisk were top performers among large-cap pharma stocks, while the stock prices of Bristol Myers and Gilead declined the most.
Stock Watch: Biotechs Sell The Family Silver
When loss-making biotech companies mix debt with sluggish sales, difficult options like restructuring and asset sales remain.
Sutro Works Toward A Better Ovarian Cancer ADC
Sutro Biopharma CEO Bill Newell spoke with Scrip about the company’s novel platform, its goal of improving folate receptor alpha-driven ovarian cancer and its business development strategy.
Company Information
- Industry
-
Pharmaceuticals
- Generic Drugs
- OTC, Consumer
- Other Names / Subsidiaries
-
- Ambit Biosciences Corporation
- Asubio Pharmaceuticals, Inc.
- Daiichi Sankyo RD Novare Co., Ltd.
- Kitasato Daiichi Sankyo K.K.
- Im Co., Ltd., Luitpold Pharmaceuticals, Inc. (American Regent, Inc., PharmaForce, Inc.)
- Plexxikon Inc.
- Ranbaxy Laboratories Ltd.
- Roxro Pharma, Inc.
- Sankyo Pharma
- Suntory Pharmaceutical
- U3 Pharma AG
- Daiichi Sankyo India Pharma Private Limited
- Kitasato Daiichi Sankyo Vaccine Co., Ltd.
- Zenotech Laboratories Ltd.
- Daiichi Sankyo Vietnam Company Limited.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice